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Mef2 transcription factors have been strongly linked with early heart development. D-mef2 is required
for heart formation in Drosophila, but whether Mef2 is essential for vertebrate cardiomyocyte (CM)
differentiation is unclear. In mice, although Mef2c is expressed in all CMs, targeted deletion of Mef2c
causes lethal loss of second heart ﬁeld (SHF) derivatives and failure of cardiac looping, but ﬁrst heart
ﬁeld CMs can differentiate. Here we examine Mef2 function in early heart development in zebraﬁsh.
Two Mef2c genes exist in zebraﬁsh, mef2ca and mef2cb. Both are expressed similarly in the bilateral
heart ﬁelds but mef2cb is strongly expressed in the heart poles at the primitive heart tube stage.
By using ﬁsh mutants for mef2ca and mef2cb and antisense morpholinos to knock down either or both
Mef2cs, we show that Mef2ca and Mef2cb have essential but redundant roles in myocardial
differentiation. Loss of both Mef2ca and Mef2cb function does not interfere with early cardiogenic
markers such as nkx2.5, gata4 and hand2 but results in a dramatic loss of expression of sarcomeric genes
and myocardial markers such as bmp4, nppa, smyd1b and late nkx2.5mRNA. Rare residual CMs observed
in mef2ca;mef2cb double mutants are ablated by a morpholino capable of knocking down other Mef2s.
Mef2cb over-expression activates bmp4 within the cardiogenic region, but no ectopic CMs are formed.
Surprisingly, anterior mesoderm and other tissues become skeletal muscle.Mef2ca single mutants have
delayed heart development, but form an apparently normal heart. Mef2cb single mutants have a
functional heart and are viable adults. Our results show that the key role of Mef2c in myocardial
differentiation is conserved throughout the vertebrate heart.
& 2012 Elsevier Inc. All rights reserved.Introduction
Congenital heart defects occur in almost 1% of human births,
which highlights the complexity of building the heart (Bruneau,
2008). In recent years, it has become clear that mammalian and
avian hearts are built from two pools of progenitor cells: ﬁrst
heart ﬁeld (FHF) cells generate the early cardiac tube and
contribute to the left ventricle, atrioventricular canal (AVC) and
atria, whereas the second heart ﬁeld (SHF), also referred to as the
anterior heart ﬁeld, contributes to the outﬂow tract (OFT), right
ventricle, and inﬂow region (Buckingham et al., 2005; Rochais
et al., 2009). The SHF is the main source of myocardial progenitors
added at a later stage to the arterial and venous poles of the heart
(Cai et al., 2003; Kelly et al., 2001; Mjaatvedt et al., 2001; Waldo
et al., 2001). Recent studies have suggested that, like the amniotell rights reserved.
House, Guy’s Campus, King’s
486435.heart, zebraﬁsh heart is built from FHF and SHF progenitor cell
pools. Whereas the FHF is the source of cells contributing to the
primitive heart tube, the putative SHF provides cells that are
added to the two poles of the heart tube, and build the structures
at the inﬂow and outﬂow tract (de Pater et al., 2009; Grimes et al.,
2010, 2006; Hami et al., 2011; Lazic and Scott, 2011; Zhou et al.,
2011). This provides a new opportunity to increase understanding
of the molecular regulation of cardiomyogenesis.
Myocyte enhancer factor 2 (Mef2) transcription factors are key
cardiomyogenic regulators, but their role in vertebrate heart
development remains uncertain. In Drosophila, the single Mef2,
D-mef2 is essential for the formation of all muscle types, including
the heart. In D-mef2 mutants, cardiomyocyte (CM) precursors
are properly speciﬁed and positioned, but fail to differentiate
(Lilly et al., 1995; Ranganayakulu et al., 1995). In vertebrates, the
Mef2 family of transcription factors has four members Mef2A, B, C
and D (Breitbart et al., 1993; McDermott et al., 1993; Pollock and
Treisman, 1991). Cell culture analyses implicate Mef2 activity,
and particularly Mef2c, in CM differentiation (Ieda et al., 2010;
Karamboulas et al., 2006). Although Mef2c is expressed during
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mutants, which die at E9.5 from gross heart defects. These
mutants have only a single ventricular chamber, abnormalities
in the inﬂow and outﬂow tracts and defective cardiac looping
reminiscent of SHF defects (Bi et al., 1999; Edmondson et al.,
1994; Lin et al., 1998, 1997b; Verzi et al., 2005; Vong et al., 2006).
Thus, in mice, there is a clear discrepancy between the strong SHF
phenotype of Mef2c loss of function and the fact that Mef2c is
expressed throughout the myocardium. It has been suggested
that other Mef2 proteins may help drive FHF CM differentiation
(Lin et al., 1997b; Vong et al., 2006). Other Mef2 genes are
expressed in murine CMs, but are not, individually, essential for
their formation. Mice mutant in Mef2d appear normal, whereas
mutants lacking Mef2a form a myocardium but exhibit perinatal
lethality from late cardiovascular defects (Arnold et al., 2007;
Naya et al., 2002). Mef2b is expressed in early heart development
(Molkentin et al., 1996b), but mice null for Mef2b have not been
described. Thus, studies in mice have so far failed to determine
whether Mef2 activity is essential for all CM differentiation.
Zebraﬁsh have the advantages of surviving for several days
without a heart and having two Mef2c genes, mef2ca and mef2cb
(Hinits and Hughes, 2007; Miller et al., 2007; Ticho et al., 1996).
Mef2ca is expressed in zebraﬁsh heart (Ticho et al., 1996). Mef2cb
is expressed in both FHF and SHF myocardium and, like loss of
Mef2c function in mouse, mef2cb knockdown with morpholinos
(MOs) has been shown to eliminate a subset of SHF CMs at the
arterial pole (Lazic and Scott, 2011). A combinatorial loss of
function analysis is therefore needed to establish the role Mef2
in the early steps of CM differentiation.
Here we show that Mef2c activity controls an essential step in
CM differentiation throughout the heart, in both FHF and SHF.
By using loss- and gain-of-function models, we show that the two
zebraﬁsh Mef2c paralogues, Mef2ca and Mef2cb, control the
expression of myocardial sarcomeric genes and other markers of
CM maturation, such as nppa, smyd1b and bmp4, reminiscent of the
function of the single Drosophila Mef2. Without Mef2ca andMef2cb,
the heart fails to form, and CMs are speciﬁed but developmentally
arrested. Embryos lacking either Mef2ca or Mef2cb alone develop a
normal heart. Together, our data reveal the essential role of Mef2
factors in the differentiation of FHF and SHF cardiomyocytes.Materials and methods
Zebraﬁsh lines and maintenance
Mutant and transgenic lines: mef2catn213 (Piotrowski et al.,
1996), mef2cab1086(Miller et al., 2007), Tg(ﬂi1a:EGFP)y1(Lawson
and Weinstein, 2002), Tg(myl7:EGFP)twu26 (Huang et al., 2003),
Tg(–5.1myl7:nDsRed2)f2 (Mably et al., 2003) and mef2cab1086
;Tg(myl7:EGFP)twu26 were maintained on King’s wild type back-
ground. Mef2cbfh288 mutant allele was identiﬁed by TILLING
(Draper et al., 2004) in the nAB background (http://labs.fhcrc.
org/moens/Tilling_Mutants/index.html), and was further cleaned
of linked contaminating mutations. Further crossing created the
double mutant lines mef2cab1086;mef2cbfh288 and mef2cab1086;-
mef2cbfh288;Tg(myl7:EGFP)twu26. Staging and husbandry were as
described (Westerﬁeld, 1995). Genotyping was performed by
sequencing of PCR products ampliﬁed from ﬁn clip or embryo
genomic DNA using primers 50-AAAGCAGGCAAATAGAAAAACACT-
30 and 50-AAAAGGCCAAACTCAACAGGAACT-30 for b1086 allele,
50-GGAAGAAGCGCTGTATTTAGGAC-30 and 50-ATATCTGTGCTGGC-
GTACTGG-30 for fh288 allele and other methods in http://labs.fhcrc.
org/moens/Tilling_Mutants/index.html).Cloning of over-expression and other plasmids
pHS-mef2cb-IRES-GFP was made by cloning the full-length
coding sequence of mef2cb (with four introduced morpholino
mismatches) generated by PCR using the primers 50-CGCTCTA-
GAATGGGACGAAAGAAAATTCAGATCACACGG-30 and 50-GTCGACT-
CATGTGGCCCACCCTTCCGAGA-30 into the XbaI and SalI sites of
hsp70-4-MCS-IRES-mGFP6 plasmid (Hinits and Hughes, 2007).
DNA sequence was veriﬁed. Mef2cb mRNA was made with
mMESSAGE mMACHINE kit from a linear DNA fragment contain-
ing the full CDS of mef2cb ﬂanked by b-globin UTRs, which was
made by a two-step PCR. First, two PCR products were ampliﬁed by
using the following primers: T3 and 50-AATTTTCTTTCGTCCCAT-
GAGCTCGATATCTCTCT-30;
T7U and 50-TCTCGGAAGGGTGGGCCACATGAGTCGACGGATCCAGAT-
CTGG-30 on pbUT3 template (Hinits et al., 2009). Second, by using
T3 and T7U primers on a template mix of pHS-mef2cb-IRES-GFP plus
the two PCR products generated at the ﬁrst step, a linear template
with T7 and T3U ends was generated and conﬁrmed by sequencing.
pCMV:mef2cb-GFP was constructed by amplifying a fragment
of themef2cb gene 50UTR including 166 bp immediately upstream
and 25 bp downstream from the start codon with primers:
50-AGATCTAAGCTTGTACAGCTACTGGAATCTTTGAAC-30 and 50-
AGATCTGAATTCTGATCTGAATCTTTTTTCTCCCCAT-30 and cloning
into EcoRI/HindIII digested pEGFP-N1 (Clontech) in frame with
EGFP and was sequence veriﬁed.mRNA in situ hybridisation
In situ mRNA hybridization was performed as described pre-
viously (Hinits et al., 2009). To avoid cross-reactivity between
mef2ca and mef2cb probes, for each gene we used two different
probes, one containing only 30UTR sequences and the other having
part of the coding sequence. The two mef2ca probes gave identical
patterns of expression (data not shown). We therefore used the
longer, original probe used by Ticho and colleagues (Ticho et al.,
1996). The mef2cb probe containing CDS as well as 30UTR (IMAGE:
6519749) hybridized strongly to all of the domains detected by the
30UTR only probe and additionally marked expression in the
cephalic vascular system and was therefore preferred. For mef2aa,
a plasmid containing the full CDS, MGC:55208, was used for PCR
with the following primers (reverse primer contains T3 site)
50-TGTACGGAAGTGTTACTTCTGCTC-30 and 50-GGATCCATTAACCCT-
CACTAAAGGGAAGGCCGCGACCTGCAGCTC-30 (Thisse and Thisse,
2005). Other probes used were: myl7, vmhc (Yelon et al., 1999),
bmp4 (Walsh and Stainier, 2001), hand2 (eu880, Thisse et al., 2005),
nkx2.5 (Lee et al., 1996), nppa (Berdougo et al., 2003), tbx20
(Ahn et al., 2000), gata4, gata5, gata6 (Reiter et al., 1999) smbpc, tnnc,
(Xu et al., 2000), egr2b (Oxtoby and Jowett, 1993), ntl (Schulte-Merker
et al., 1992), kdrl (Thompson et al., 1998) and cdh5 (Larson et al.,
2004). Embryos were photographed as wholemounts on Olympus
DP70 or dissected and ﬂatmounted in glycerol and photographed on
a Zeiss Axiophot with Axiocam using Openlab software.Embryo staining
Anti-Mef2 (Santa Cruz) and Anti-Mef2c (McDermott et al.,
1993) were used as described (Hinits and Hughes, 2007). Anti-
Mef2 can detect Mef2cb protein, as high-level nuclear expression
was detected in a mosaic fashion after injecting BAC CH211-
202E12 DNA, containing themef2cb locus into embryos (Fig. S1A–E).
Anti-Mef2ca/cb (1:200, Anaspec) reacted similar to anti-Mef2c
and did not cross-react with other Mef2s (Fig. S2A–C). It also
detects Mef2cb, as injecting either hs-mef2cb-IRES-GFP plasmid
DNA (followed by a heat shock) ormef2cbmRNA at 1–2 cell stage,
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GFP (Fig. S1F and G). Other primary antibodies used were against
sarcomeric myosin heavy chain (MyHC; A4.1025 (Blagden et al.,
1997) or MF20 (DSHB, Iowa)), slow MyHC (F59, (Devoto et al.,
1996)), DM-Grasp (zn5, ZIRC), Elastin (Miao et al., 2007), GFP
(rabbit, Torrey Pines or chicken, Abcam ab13970) or RFP (rabbit
PM0005, Medical and Biological Laboratories). Secondary antibodies
were either HRP-conjugated (Vector) or Alexa dye-conjugated
(Invitrogen). Embryos for immunohistochemistry were ﬁxed in 4%
PFA for 30 min to 2 h (except embryos stained with DAF2DA were
ﬁxed in 2% PFA for 30 min) and stained as described (Hinits and
Hughes, 2007). Embryos were mounted in Citiﬂuor (Agar) or low
melting point agarose. Confocal images collected on a Zeiss LSM510
and some processed using Volocity software. DAF-2 DA (Santa Cruz)
was used as described (Grimes et al., 2006).
Embryo manipulation
All morpholinos, plasmid and BAC DNA were injected into 1–2
cell stage embryos.mef2d/cMO andmef2ca ATGMOwere described
(Hinits and Hughes, 2007). Mef2cb ATG MO (50-TGTCCCCGTC-
TTTTCGTCTCTCTCT-30, Gene-Tools, 0.25 ng) and mef2cb E1I1 MO
(50-TTCCGGTCAGCGTGACTCACCTGTC-30, Gene-Tools, 1 ng) were
used for Mef2cb knockdown. To evaluate the effectiveness of
mef2cb ATG MO, we co-injected pCMV:mef2cb-GFP with mef2cb
ATGMO or other control MOs (Fig. S3A and B). Mef2cb E1I1 MOwas
checked by RT-PCR using primers 50-CACACGGATTATGGATGAACG-
30 and 50-TCCTTTGACTCTGGGCTGTGG-30 matching the ﬁrst and the
third exons of mef2cb, which produces the 321 bp normal splicing
product and an additional PCR product of 403 bp. Sequencing
indicated the use of a hidden splice donor site inside intron 1,
and so creating an aberrant transcript with a premature stop codon
(Fig. S3C). Hand2 MO 50-CCTCCAACTAAACTCATGGCGACAG-30) was
used as described (Maves et al., 2009).Results
Mef2ca and mef2cb are the only Mef2 orthologues expressed in the
early phases of heart development in zebraﬁsh
Developing zebraﬁsh hearts were screened for expression of
Mef2 family transcription factors. Four Mef2 orthologues areFig. 1. Mef2ca andmef2cb expression during early cardiogenesis. In situ mRNA hybridisa
(A–E, G–I) and Tg(myl7:EGFP) (F) in dorsal (A and B) or lateral (C–E) views of wholemount
A and B. Mef2ca and mef2cb mRNAs accumulate in the bilateral heart ﬁelds in ALPM
rhombomeres 3 and 5, and ntl expression in the notochord positions the row of ventral
notmef2aamRNA (C). F. Confocal stack of Tg(myl7:EGFP) heart at 25 ss showing co-local
crescent of CMs spanning the midline. H and I. By 24 hpf, both mef2ca (H) and mef2c
strongly in the venous (blue arrow) and arterial (pink arrow) poles of the heart. Scale
ﬁgure legend, the reader is referred to the web version of this article.)known in zebraﬁsh: mef2aa (previously named mef2a), mef2ca
(previously named mef2c), mef2cb and mef2d (Hinits and Hughes,
2007; Lazic and Scott, 2011; Miller et al., 2007; Ticho et al., 1996).
Two more, mef2ab and mef2b, were identiﬁed bioinformatically as
orthologues of mammalian Mef2a and Mef2b, respectively. Only
mef2ca, mef2cb and mef2aa genes were detectably expressed in
the developing zebraﬁsh heart (Fig. 1 and data not shown).Mef2ca
mRNA accumulated in cells of the anterior lateral plate mesoderm
(ALPM) from around 6 ss (6 somite stage, data not shown), and
was strong at 10–13 ss. Expression persisted as the heart ﬁelds
fuse to form the primitive heart tube (Fig. 1A and D) (Hinits and
Hughes, 2007; Ticho et al., 1996). At 24 hpf, mef2ca was still
detected weakly throughout the heart but was downregulated
thereafter (Fig. 1H and data not shown). Mef2cb mRNA accumu-
lated weakly in differentiated somitic adaxial cells in the bilateral
heart ﬁelds as early as 7–8 ss (Fig. 1B and E and data not shown,
see also (Lazic and Scott, 2011)). During the heart cone stage
mef2cb mRNA and Mef2c protein had accumulated in the differ-
entiating CMs (Fig. 1F and G). Around 24 hpf, mef2cb mRNA
pattern became distinct from that of mef2ca mRNA. Mef2cb was
detected in the arterial and venous poles of the heart, in addition
to the overall weak signal in the rest of the heart tube (Fig. 1I).
Mef2cb mRNA was present without detectable mef2ca mRNA in
the telencephalon and vascular system (Fig. S4A). Conversely,
mef2cb mRNA was absent in the branchial arches that express
mef2ca highly (Miller et al., 2007; Ticho et al., 1996). Mef2aa
mRNA was not apparent before FHF CMs differentiate, but was
detected in the heart at later stages than mef2ca and mef2cb and
remained until at least 48 hpf (Fig. 1C and data not shown). Thus,
the main Mef2 genes expressed during early cardiac development
are mef2ca and mef2cb.Mef2ca and mef2cb are required for myocardial differentiation
To test the role of Mef2c during early cardiac development, we
analysed a double mef2cab1086;mef2cbfh288 mutant made by crossing
double heterozygotes for mef2caþ /b1086 (hoover) (Hinits and Hughes,
2007; Miller et al., 2007) and a novelmef2cbfh288 allele with an A to T
single point mutation changing Arg at residue 24 of the Mef2cb
protein to a stop codon early in the MADS domain, thereby generat-
ing a predicted null mutation (http://labs.fhcrc.org/moens/Tilling_-
Mutants/index.html; (Molkentin et al., 1996a; Yu et al., 1992)). Thetion of indicated genes, or immunodetection of Mef2ca/cb protein (G) for wild type
embryos or in ﬂatmounts of dorsal views of the cardiac region, anterior to top (F–I).
(black arrowheads) and adaxial cells (green arrowhead). C–E. Egr2b expression in
cells in the ALPM (black arrowheads; D and E) that contain mef2ca and mef2cb, but
isation ofmef2cbmRNA (Fast Red) and EGFP. G.Mef2c protein in nuclei of a similar
b (I) mRNAs are detected weakly in the heart tube, but mef2cb also accumulates
¼100 mm (A–F), 20 mm (G–I). (For interpretation of the references to color in this
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In wild type embryos, differentiation of myocardial precursors
begins around 14 ss in ALPM, and is marked by accumulation of
mRNAs encoding sarcomeric protein genes such as myl7 and vmhc
(Fig. 2A and (Yelon et al., 1999)). Close to 1/16th of embryos from a
mef2caþ /b1086;mef2cbþ /fh288 in-cross entirely lacked these markers
at 15 ss (Fig. 2F, quantiﬁcation of all experiments is presented in
Table S1). We conﬁrmed this result in amef2ca singlemutant injected
with mef2cb MO (either of two mef2ca null mutant alleles injected
with either of two mef2cb MOs lacked markers in one quarter of
embryos), the mef2cb null mutant injected with mef2ca MO, or dual
mef2ca and mef2cb MOs (Fig. 2B, S5A and B). Hereafter, we refer to
embryos lacking Mef2c activity as ‘dual loss of function’ irrespective
of the combination of mutant allele and/or MOs employed; all lack
the vast majority of differentiated CMs. We also injected wild type
embryos with a singlemef2d/c ATGMOwhich we previously showed
ablates several Mef2 proteins due to the high degree of conservation
between various Mef2 genes at the beginning of the coding region
(Hinits and Hughes, 2007)). This MO also ablated all CMs differentia-
tion at 15 ss (Fig. S5A and B).
Zebraﬁsh smyd1b mRNA normally marks differentiating CMs
in the FHF from 13 ss, and is an orthologue of mouse Smyd1/Bop,
a known Mef2c target (Phan et al., 2005). Mef2ca;mef2cb dual loss
of function embryos lacked smyd1bmRNA both before (13 ss) and
after (17 ss) the time of CM differentiation (Fig. 2A and B and data
not shown). At 24 ss, such embryos had no sarcomeric myosin
heavy chain (MyHC) protein in heart, whereas this protein was
present in skeletal muscle (Fig. 2G). At 24 hpf,mef2ca;mef2cb double
mutants and other dual loss of function embryos had no beating
heart cells, and lacked almost all myl7 and vmhc mRNA and MyHC
protein in heart; however, a few residual CMs were variably present
(Fig. 3A,B and F and Fig. S6A). The residual cells had both ventricular
and atrial character, having vmhc mRNA caudally and myl7 mRNA
alone anteriorly. At this stage, mef2cbfh288 mutant embryos injected
with mef2ca MO had somewhat more cells expressing myl7 mRNAFig. 2. Early cardiomyocytes fail to differentiate after loss of Mef2c function. A–F. In
mef2cab1086þmef2cbMO (B),mef2cab1086 (C)mef2cbMO (D),mef2cbfh288 (E) andmef2cab
Loss of both mef2ca and mef2cb function greatly reduces myl7, vmhc and smyd1b mRNA
have weak myl7 and smyd1b mRNAs early, but recover later, and show no change in v
Immunostaining for MyHC (A4.1025) in 24 ss mef2cab1086;mef2cbfh288 embryos and the
lateral view, anterior to left (right panel). No MyHC is detected in the heart, whereas sthan the double mef2ca;mef2cb mutants, and their heart had a thin
string-like shape (Fig. S6B). Although mef2ca morphants phenocop-
ied the jaw defects seen in the mutant at 5 dpf ((Miller et al., 2007)
and data not shown), this ﬁnding suggests incomplete knockdown
of Mef2ca protein by mef2ca MO. Conversely, using the mef2d/cMO
we observed no cardiac cells expressing MyHC or a variety of other
myocardial markers (Fig. 3G –I and data not shown). In addition,
mRNAs encoding bmp4, smyd1b and atrial natriuretic factor (nppa),
all markers of maturing CMs, were absent (Fig. 3B, F and J). Thus,
lack of both Mef2ca and Mef2cb results in failure of CM differentia-
tion and heart formation.
By 48 hpf, double mef2ca;mef2cb mutant embryos had peri-
cardial oedema accompanied by lack of most myocardial cells
(Fig. 4A, S6C). Around 30 residual CMs were present in small
beating tube-shaped structure(s) forming either one or two zones
(usually in the location of the venous pole, occasionally in both
poles, and, more rarely, in a single string-like structure; Fig. 4B
and C and data not shown). Wild type hearts had undergone
looping by this stage and two chambers are readily distinguished.
Double in situ hybridisation for myl7 and vmhc marks the
ventricular cells with both mRNAs, whereas atrial cells express
myl7 only. Each small residual tube in a mef2ca;mef2cb double
mutant had either the ventricular or the atrial expression pattern
appropriate to its position in the cardiac region (Fig. 4B). nppa and
bmp4 mRNAs are missing or weakly restricted to residual regions
(Fig. 4E and F). At 72 hpf, an incross of mef2caþ /b1086;mef2cbþ /fh288;
Tg(myl7:EGFP)twu26 had one or two residual GFPþ tube-shaped
structures in double mutant embryos, of which 80% (n¼17) were
beating (Fig. 4G and data not shown). Thus, lack of both Mef2ca and
Mef2cb results in failure of most CM differentiation and heart
formation, although a few cells showing either atrial or ventricular
fates are able to differentiate after 24 hpf.
In contrast, hearts of mef2d/c morphant embryos had a more
severe phenotype; neither MyHC nor atrial-speciﬁc MyHC immu-
nostaining was detected in mef2d/c morphants (Fig. 4D). No Mef2situ mRNA hybridisation for myl7, vmhc and smyd1b in wild type control (A),
1086;mef2cbfh288 (F) embryos, shown in wholemounts in dorsal view, anterior to top.
s in the bilateral heart ﬁelds (arrowheads; A,B and F). Mef2cab1086 mutant embryos
mhc (C). Mef2cb single morphants or mef2cbfh288 mutant show no changes (D). G.
ir siblings, shown in wholemounts in dorsal view, anterior to top (left panel) and
omitic muscle appears normal (white arrowheads). Scale¼100 mm.
Fig. 3. Redundant and speciﬁc functions of Mef2ca and Mef2cb drive cardiomyogenesis and heart tube formation. Immunodetection of MyHC (confocal stacks, top panels)
or in situ mRNA hybridisation for indicated genes (A–F, lower panels and G-J) in hearts of 24 hpf zebraﬁsh embryos shown in a dorsal view, anterior to top. A,B and F.
Loss of both mef2ca (tn213 allele, in MyHC and b1086 allele, in bmp4 and myl7þvmhc) and mef2cb function (B and F) led to lack of all markers, compared with control (A).
Note the few cells expressing myl7 only (black arrowhead) or both myl7 and vmhc (white arrowhead). C. Mef2camutants have a normal heart. D and E. Mef2cb morphants
have a shortened heart with substantial loss of both atrial and ventricular volume, yet mef2cbfh288 mutants have a normal heart. G–I. Loss of Mef2c function with mef2d/c
MO ablated all actin (acta1b, G), tnnc2 (H), mybpc1 (I) and nppa (J) mRNAs. Scale¼100 mm.
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morphants (data not shown). Lack of additional Mef2s in mef2d/c
MO appears to prevent residual CM differentiation.
We also tested whether non-myocardial cells that form the
bulbus arteriosus can differentiate when lacking Mef2ca and Mef2cb.
Double mutant embryos had a smaller than normal bulbus arter-
iosus structure marked by Elastin immunostaining (Grimes et al.;
Grimes et al., 2006; Hami et al.; Lazic and Scott, 2011; Miao et al.,
2007), but the bulbus size was reduced in proportion to that of the
residual CM tube structure in the arterial pole (Fig. 4G). Thus, Mef2c
activity directly or indirectly controls bulbus arteriosus size.
Mef2ca and mef2cb are required for a late step in cardiomyocyte
differentiation
To deﬁne the role of Mef2 proteins in the cascade of events
leading to CM differentiation, we examined mef2ca;mef2cb dual
loss of function embryos at early stages when myocardial pre-
cursors reside bilaterally within the ALPM. Speciﬁed CMs in the
ALPM express a transcriptional program that includes several
GATA, Tbx, Nkx2 and Hand2 factors (Begemann and Ingham,
2000; Reiter et al., 1999; Ruvinsky et al., 2000; Serbedzija et al.,
1998; Yelon et al., 1999, 2000). At 12 ss, nkx2.5, gata4,5,6 and
hand2 mRNAs appeared indistinguishable in dual loss of function
embryos compared to controls (Fig. 5A–C and S5E). Congruently,
all embryos from mef2cbþ /b1086;mef2cbþ /fh288 incross analysed at
this stage showed similar expression of these mRNAs (data not
shown). By 22 ss, expression of various genes that are part of themyocardial program, such as tbx20 and gata6, began to show
defects in dual loss of function embryos and mef2d/c MO by
lacking the characteristic ring of expression around the endocar-
dium and had a disorganised pattern at the midline (Fig. 5D and E).
Paralleling this defect there was a failure of nkx2.5 mRNA main-
tenance. Whereas early nkx2.5 expression was unaffected by loss of
Mef2ca and Mef2cb function, its mRNA was later lost, presumably
due to the lack of differentiated CMs (Fig. 5A and F). Similarly,
smyd1b and most bmp4 mRNA was lost (Fig. 2B and S5C and D),
indicating their role in the maturation of differentiated CMs that are
lost after dual loss of function. Thus, Mef2cs function late, during
sarcomeric differentiation of CMs.
In order to place the function of Mef2cs in relation to other factors
implicated in CM differentiation, we examined the bHLH transcrip-
tion factor hand2, which promotes CM differentiation, especially in
ventricle (Yelon et al., 2000). In mice, it has been suggested that
Mef2c is upstream of Hand2, as expression of Hand2 was reduced in
Mef2c null mice (Lin et al., 1997b). However, we found that, at
20–25 ss, hand2 mRNA levels appear up-regulated after mef2ca;-
mef2cb dual loss of function in a wide sheet cells in the prospective
cardiac region (Fig. 5G). Although hand2 mRNA normally persists in
the heart tube, its levels are down-regulated in the pre-cardiac region
as CMs differentiate (Yelon et al., 2000). These data indicate that CM
development was arrested in the absence of Mef2 function. Although
hand2 mRNA expression precedes that of mef2ca and mef2cb in the
ALPM, both are expressed in hand2 mutants and morphants, ((Yelon
et al., 2000), and Fig. S7A and B). Thus, it is not likely that mef2ca/
mef2cb are targets for Hand2 in zebraﬁsh.
Fig. 4. Loss of Mef2c function abolishes sarcomeric gene expression. Hearts of 48–50 hpf (A–F) or 72 hpf (G) mef2cab1086;mef2cbfh288 mutant embryos and their siblings in
bright ﬁeld (A), after immunodetection (C,D and G) or in situ mRNA hybridisation (B,E and F) shown in lateral view, anterior to left (A and G) or ventral (B–F) view, anterior
to top. A. mef2cab1086;mef2cbfh288 embryos had a tiny residual heart (arrow) and cardiac chamber edema. B,E and F. Double mutant embryos lacked almost all myl7, vmhc,
bmp4 and nppa mRNAs as well as MyHC and Mef2 proteins in ventricle (v), atrium (a) or AV canal (red arrows in F) except for one (arrows in C,E) or two small heart
structures expressing these markers. C. Confocal stack showing genotyped double mutant expressing low levels MyHC and nuclear Mef2 in a residual myocardial tissue.
Sibling presented is mef2caþ /b1086;mef2cbþ /þ . D. No MyHC or atrial MyHC is detected inmef2d/cmorphants. G. Immunodetection for GFP (atrium and ventricle, green) and
Elastin (bulbus arteriosus, ba) in hearts of three different genotyped mef2cab1086;mef2cbfh288;Tg(myl7:EGFP)twu26 showing variation in residual differentiated myocardial
and bulbus tissue, compared to the normal heart of a mef2caþ /b1086;mef2cbþ /fh288;Tg(myl7:EGFP)twu26 sibling. Scale¼100 mm. (For interpretation of the references to color
in this ﬁgure legend, the reader is referred to the web version of this article.)
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The lack of a clear cardiac cone revealed by tbx20 and gata6
mRNA in dual loss of function embryos suggested that embryos
lacking Mef2ca and Mef2cb may have defects in the endocardium
or, more generally, in endothelium (Fig. 5D and E). Indeed, mef2cb
mRNA is clearly detected in vasculature (Fig. S4A), consistent with
the presence in mef2ca, mef2cb and mouse Mef2c upstream reg-
ulatory regions of a FOX:ETS binding motif capable of driving GFP in
zebraﬁsh endothelium (De Val et al., 2008). However, endothelial
markers ﬂi-1, kdr (ﬂk-1) and cdh5 are relatively unperturbed in
vasculature of double mef2ca;mef2cb mutants and in mef2d/c MO
embryos (Fig. S4B–E). Endocardial markers were also present in
dual loss of function embryos. Whereas in 22 ss control embryos a
ring of myl7þ CMs surrounds a small circle of cdh5þ endocardial
cells, in dual loss of function andmef2d/cMO embryos lacking heart
myl7 mRNA, cdh5 mRNA was not only present but even expanded
and up-regulated (Fig. 5H). Intriguingly, by 48 hpf, endothelial cells
marked with cdh5 mRNA were abnormally organised in the cardiac
region where the heart had failed to form (Fig. 5I). Thus, lack of
myocardial differentiation leads to the disorganisation of other
layers of the heart.
Over-expression of mef2cb dominantly changes cell fate
Dual loss of function shows Mef2c factors are necessary for
myocardial differentiation. To test whether Mef2 is also sufﬁcientfor CM differentiation, we used a gain of function approach.
Embryos injected at the 1–2 cell stage with RNA encoding mef2cb
had widespread ectopic muscle in the head region (Fig. 6A and
S1G). Most ectopic muscle was composed of elongated cells
expressing high levels of MyHC and smyd1b mRNA and lacking
bmp4 mRNA, and therefore may differ from CMs (Fig. 6A–C).
Interestingly,mef2cbmRNA injection did up-regulate bmp4mRNA
in many cells in a rectangle within the cardiogenic region, but not
elsewhere in the embryo (Fig. 6C). Nevertheless, few cells in the
rectangle appeared to form CMs, and hearts in such embryos were
not bigger than normal (Fig. 6A). Taken together, these data
indicate that although Mef2cb can induce bmp4 in the cardiogenic
region, Mef2cb alone is insufﬁcient to drive widespread ectopic
CM differentiation.
The elongated nature of ectopic muscle cells induced outside
the cardiogenic region by Mef2cb over-expression was reminis-
cent of skeletal muscle. To test this possibility, we used double
in situ hybridisation for myod and myl7, which exclusively mark
skeletal muscle or myocardial cells, respectively. Injection of 20
pg of mef2cb RNA caused high levels of ectopic myogenesis
accompanied by a dramatic failure of brain morphogenesis
(Fig. 6D and E). At both 14 ss and 23 ss, no ectopic myl7 expression
was found in embryos injected with mef2cb RNA, whereas many
cells in the head region expressed ectopic myod (Fig. 6D and E).
Moreover, at 23 ss, fewer CMs expressed myl7 in Mef2cb-over-
expressing embryos (Fig. 6E). In addition, cdh5þ endothelial cells
were also reduced in both endocardium and vasculature in such
embryos (Fig. 6G). The ectopic expression of the skeletal muscle
Fig. 5. Cardiomyocytes of mef2ca;mef2cb dual loss of function are speciﬁed but developmentally arrested. In situ mRNA hybridisation for indicated genes (wholemounts in
dorsal view, anterior to top, except J, ventral view). A–C. ALPM expression (arrowheads) of nkx2.5 (A), hand2 (B) and gata4 (C) at 12 ss is unaffected by lack of Mef2ca and
Mef2cb. Notochord and rhombomeres 3 and 5 are marked by ntl (blue) and egr2b (red), respectively. D,E. Tbx20 and gata6mRNAs are present but disorganised in the heart
region ofmef2d/cmorphants andmef2cab1086;mef2cbfh288 mutant embryos (lacking myl7 expression in red, E, right panel) compared to the typical ring-shape in control and
sibling embryos. F. During heart cone stage (22 ss), nkx2.5mRNA is abolished. G. hand2mRNA is enhanced in a sheet of cells spanning the cardiac region but not elsewhere.
Pharyngeal pouch expression is unchanged (white arrowheads). H, Whereas myocardial cells are undifferentiated in mef2d/c morphants and mef2cab1086;mef2cbfh288 mutants
(myl7, red), the endocardium is expanded and cdh5 is up-regulated. I. Endocardium (cdh5, arrow) lines the myocardium (myl7, red) in the normal looped heart of a sibling
embryo. In mef2ca;mef2cb mutant embryos, little endocardial makrer is co-localised with the residual myocardium (arrows). Extra cdh5-expressing tissue is detected in the
cardiac region (arrowheads). Scale¼100 mm. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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together with the depletion of cardiac and endothelial markers,
indicates that high levels of Mef2cb can dramatically alter cell
fate in the early embryo.
In order to restrict our overexpression analysis to cells nor-
mally expressing mef2cb, we drove mosaic over-expression of
mef2cb by injection of a BAC CH211-202E12 DNA, containing the
mef2cb locus. This approach leads to greatly increased expression
of genes contained within the BAC, but in normal locations (Minchin
and Hughes, 2008). The BAC also contains Dre-mir-9-5 microRNA.
mir-9 is highly expressed in the brain, and is suggested to regulate
neurogenesis, but is not expressed in zebraﬁsh heart (Leucht et al.,
2008; Wienholds et al., 2005), and thus is not predicted to effect the
heart. Injection of the BAC increased levels of mef2cb mRNA and
Mef2 protein in scattered somitic muscle, heart, telencephalon and
vasculature, regions were mef2cb is normally detected (Fig. S1A–D).
Within the cardiogenic region, patches of ectopic myl7 mRNA
appeared around the heart (Fig. 6G), and could reﬂect either ectopic
induction of CMs or their aberrant migration. Ectopic skeletal
muscle was not observed elsewhere (data not shown). Thus, the
skeletal myogenic effect of Mef2cb over-expression appears to be
restricted to certain cells in early embryos.
Lack of Mef2ca delays cardiomyocyte maturation
Dual loss of function of both mef2ca and mef2cb blocked CM
differentiation, but loss of function of either gene alone did not
prevent heart formation (Figs. 2 and 3). Analysis of two mutant
alleles of mef2ca, b1086 and tn213, revealed weaker myl7 mRNA
accumulation in FHF CMs at 15 ss, suggesting a decreased rate of
differentiation in the absence of Mef2ca (Fig. 2C and data notshown). However, vmhc expression was indistinguishable from
that in sibling and control wild type embryos (Fig. 2C and data not
shown). Consistent with the view that FHF differentiation is
retarded, smyd1b mRNA was not detected in the bilateral heart
of a quarter of mef2caþ / incross progeny at 13 ss, but appeared
normal by 17 ss (Fig. 2C). By 24 hpf, mef2ca mutant hearts had
normal shape and size as revealed by various sarcomeric genes
and bmp4 mRNA accumulation (Fig. 3C), even though Mef2
protein was greatly reduced (Fig. S2B and (Hinits and Hughes,
2007)). At 48 hpf, mef2ca mutant embryos had normal gene
expression and had undergone normal looping (Fig. S8A and B).
Mutant inﬂow and outﬂow tracts (IFT and OFT) were well-formed
and addition of new CMs in these locations occurred during the
2–3 dpf. At 5 dpf, mef2ca mutants had indistinguishable hearts
from their siblings (data not shown). Moreover, we found no
signiﬁcant difference in heart rate betweenmef2camutants,mef2ca
morphants and their respective control embryos (Fig. S8E). Taken
together with mef2ca and mef2cb expression data and the dual loss
of function results, these data suggest that eithermef2cb is the main
functional Mef2 gene in the heart, or that redundancy between
Mef2ca and Mef2cb is sufﬁcient to support a functional heart.Mef2cb mutant is viable and shows no heart defects
We next tested the function of Mef2cb in zebraﬁsh develop-
ment. Unlike mef2ca mutants, at 15 ss, mef2cb morphants had no
change of myl7 or vmhc mRNA accumulation (Fig. 2D). Expression
of smyd1b was also normal at both 13 ss and 17 ss (Fig. 2D).
Considering mef2cb mRNA accumulation at both poles of 24 hpf
hearts (Fig. 1I), we hypothesized an effect of lack of Mef2cb
Fig. 6. Mef2cb overexpression induces skeletal muscle at the expense of myo-
cardial and endothelial cells. In situ mRNA hybridisation (or immunodetection, A)
for indicated genes, shown as wholemounts in dorsal (G and C) or lateral (B and D,
top panel) views, or as ﬂatmounts in dorsal view (A and D, bottom panel, E and F).
A. Injection of mef2cb RNA results in many ectopic muscle cells expressing strong
Mef2ca/cb and MyHC at 24 hpf (white arrowheads) anterior to the ﬁrst somite
(white arrow). In the heart, MyHC and Mef2ca/cb are mosaically stronger than in
control embryos. Asterisks¼ectopic muscle. B. Smyd1b is upregulated in CMs
(white arrow), and in ectopic muscle in the head region (white arrowheads).
C. Expression of bmp4 is upregulated in much of a sheet of cardiogenic cells but
not elsewhere in the embryo. D. In 14 ss control embryos, myod mRNA is
expressed in somites (black arrowheads) and myl7 is expressed weakly in CMs
(white arrow). Embryos injected with mef2cb RNA express no ectopic myl7, but
have ectopic myod mRNA in the head region (white arrowheads). E. By 24 ss, high
levels of ectopic myod correlated with reduction or lack of myl7-expressing CMs
(right panel) and defective brain development. F. At 24 ss, mef2cb RNA-injected
embryos that had fewer myl7-expressing CMs (white arrows) also had less cdh5
expression in vascular endothelium (green arrows) and disorganised endocardium
(blue arrows). G. Compared to wild type control (leftmost panel), three examples of
embryos injected withmef2cb BAC DNA show ectopicmyl7mRNA either contiguous
with (left panels) or detached from (right panel) the arterial (ﬂanking panels) or
venous (middle panel) poles. Scale¼100 mm. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 7. Loss of mef2cb function results in no heart phenotype. In situ mRNA
hybridisation for myl7, vmhc and bmp4 (A,B, ventral view, anterior to top) and
immunodetection of DM-GRASP (zn5) and Elastin (C, lateral view, anterior to left)
of hearts at indicated stage of genotyped mef2cbfh288mutants and their siblings.
A,B. mef2cbfh288 mutants had a normal looped heart and normal expression of
chamber markers, and bmp4mRNA in OFT (blue arrow), IFT (purple arrow) and AV
canal (red arrows). C. Confocal stacks of genotyped mef2cbfh288 mutants and
siblings with a normal looped heart with developed chambers and bulbus
arteriosus. Scale¼100 mm. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)
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Scott (2011) using an ATG-MO that has only a 4 bp overlap with
ours, have reported that Mef2cb is necessary for ventricular
development and for late CM addition at the arterial pole (Lazicand Scott, 2011). We also ﬁnd that mef2cb morphants had smaller
hearts at 24 hpf with both cardiac chambers appear defective
(Fig. 3D). By 48 hpf, Mef2cb morphant hearts did not undergo
looping, and their linear hearts showed mis-regulation various
genes (Fig. S9A–C and data not shown). Other, non-myocardial
derivatives, such as bulbus arteriosus that is marked by DAF-2 DA
and Elastin (Grimes et al.; Grimes et al., 2006; Hami et al.; Lazic and
Scott, 2011; Miao et al., 2007) were missing at 72 hpf (Fig. S9C and
D). In order to test these results we analysed the TILLING mutant
mef2cbfh288 (see earlier section). We did not observe any heart
phenotype in embryos from various incrosses of mef2cbþ /fh288 ﬁsh.
Moreover, progeny from incrosses that were allowed to grow to
adulthood revealed close to expected numbers of adult homozy-
gous mutants mef2cbfh288/fh288 (5/14, 35% compared with 25%
expected). These adults are healthy and able to breed. In agreement
with these facts, genotyped mef2cbfh288/fh288 homozygous mutants
had no change in myl7, vmhc or bmp4 mRNAs or MyHC protein
accumulation at 15 ss or 24 hpf (Figs. 2E, 3E). Hearts were looped
and expressed normal levels and pattern of myl7, vmhc and bmp4
mRNAs (Fig. 7A and B). The bulbus arteriosus also formed correctly
and expressed Elastin (Fig. 7C). Thus, mef2cbfh288 mutants have
normal hearts, at least under normal growing conditionsDiscussion
The current work makes ﬁve major points. First, Mef2c homo-
logues are essential for heart formation in zebraﬁsh. Second, early
Mef2 function during heart development is in a speciﬁc step of
CM differentiation that follows speciﬁcation. Third, Mef2ca and
Mef2cb function redundantly to drive differentiation of both early
and late added CMs. Fourth, both mef2ca and mef2cb single
mutants have a seemingly normal heart. Fifth, Mef2cb, if mis-
expressed outside the cardiogenic region during early embryonic
development, has the ability to override cell fates and convert
cells to skeletal muscle. These ﬁndings provide experimental
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essential for vertebrate CM differentiation.
Mef2 role in sarcomeric muscle differentiation
Our data show that Mef2 activity is required for differentiation
of all CMs of both FHF and the putative SHF of zebraﬁsh. Sarcomeric
gene expression was lost when the two Mef2c paralogues in
zebraﬁsh, mef2ca and mef2cb, were knocked down by morpholinos
or in genetic null mutants. Mef2c does not act alone; sarcomeric
genes such as myl7 and vmhc also require other transcription
factors for their expression in CMs (Peterkin et al., 2007; Yelon
et al., 2000 ). Nevertheless, to date, we have found no cardiac
sarcomeric gene that is normally expressed without Mef2 activity.
Expression of many other genes, including smyd1b, nppa and bmp4,
that are involved in the maturation of CMs were also ablated after
Mef2 loss of function. Mammalian orthologues of several of these
genes are direct Mef2c targets, including Bop (Smyd1) and Anf
(Nppa) (Morin et al., 2000; Phan et al., 2005; Zang et al., 2004).
Bmp4 is suggested to function by increasing myoﬁbrillar gene
expression, turning cardioblasts into beating CMs (Tirosh-Finkel
et al., 2010). Our ﬁndings place Mef2 function in CM differentiation
at a step that precedes Bmp4 expression, although it is not clear if
bmp4 is a direct Mef2c target.
Mef2c is clearly required at a later step than Nkx2.5, GATA and
Hand2 transcription factors. Cardiac precursors lacking bothMef2ca
and Mef2cb express nkx2.5 until the point of differentiation into
contractile CMs. When differentiation fails, nkx2.5 expression is lost,
suggesting that CM precursors do not simply remain in an imma-
ture state. Other manipulations, that prevent differentiation of CMs,
such as ectopic expression of dominant negative BMP receptors or
gata6 MO, also speciﬁcally block late nkx2.5 expression (Peterkin
et al., 2003; Shi et al., 2000). Combined loss of function of GATA
factors prevents CM speciﬁcation prior to mef2ca expression,
whereas lack of GATA5 or GATA6 alone causes cardia biﬁda
(Holtzinger and Evans, 2007; Peterkin et al., 2003, 2007). Loss of
function of hand2, the only Hand factor in the current zebraﬁsh
genome, does not preventmef2ca andmef2cb expression but results
in cardia biﬁda with reduced CM number (Yelon et al., 2000).
In contrast, heart cells lacking Mef2 are speciﬁed and migrate
normally to the midline, but fail to differentiate.Mef2ca;mef2cb dual
loss of function embryos retain high levels of hand2 mRNA in the
cardiogenic region, suggesting a developmental arrest at a pre-
differentiation step involving Hand2 expression. Loss of Mef2c in
the mouse, on the other hand, leads to a mild delay in hand1 and
absence of late hand2 expression (Lin et al., 1997b; Vong et al.,
2006). As far as we are aware, early Hand2 expression remains to be
investigated in Mef2c null mice. The up-regulation of both hand2
and the endocardial marker cdh5 in Mef2 loss of function zebraﬁsh
embryos suggests that failure of CM differentiation has effects
beyond myocardium.
The mef2d/c morpholino, which targets mef2d, both mef2cs and
possibly mef2aa and mef2b (Hinits and Hughes, 2007), causes a
complete loss of cardiomyogenesis, showing that Mef2 is essential
for CM differentiation. The stronger effect of mef2d/c MO when
compared with other dual loss of function mutant or morphant
combinations, which ablate most but not all CMs, strongly suggests
that other Mef2 proteins are responsible for the residual cardio-
myogenesis in mef2ca;mef2cb double mutants. Strong evidence
supporting this view is that the residual CMs in double mutants
have Mef2, but not Mef2c, immunoreactivity. Indeed,mef2aamRNA
is detected in the residual myocardial regions of double mutants
(data not shown). We conclude that mef2d/c MO is likely to knock
down Mef2aa activity sufﬁciently to prevent CM differentiation,
despite six bases of mismatch. Moreover, Mef2aa appears, like the
Mef2cs, to be able to drive CM differentiation.Mef2-dependency of zebraﬁsh myocardium is remarkably
similar to that in Drosophila. The single Mef2 factor in Drosophila,
D-Mef2, is essential for expression of sarcomeric genes in the ﬂy
heart in the dorsal vessel, but is not required for expression of
speciﬁcation genes. Moreover, the dorsal vessel is more sensitive
to the lack of D-Mef2 than is body wall (i.e., skeletal) muscle (Lilly
et al., 1995; Ranganayakulu et al., 1995). In zebraﬁsh skeletal
muscle, Myogenic Regulatory Factors (MRFs) drive expression of
some sarcomeric genes after knockdown of Mef2 activity (Hinits
and Hughes, 2007; Hinits et al., 2009, 2011). Thus, cardiac and
skeletal myocytes may differ in Mef2 dependency for terminal
differentiation. Nevertheless, both in skeletal and cardiac muscle,
Mef2c expression parallels differentiation of the contractile phe-
notype (Hinits and Hughes, 2007; Potthoff et al., 2007). Our
ﬁndings suggest a deep conservation of function of Mef2 in heart
development through animal evolution and contrast with the
divergence of function of MRFs between vertebrates and Drosophila.
Redundant roles for Mef2ca and Mef2cb during
cardiac development
The FHF had early maturation defects in mef2ca mutants that
were not observed in mef2cb morphants. Both mef2ca probable
null alleles (Miller et al., 2007) and morphants showed a short
developmental delay affecting some sarcomeric and maturation
genes in the FHF. Mef2ca deﬁcient hearts recovered well, but
whether they are normal in all respects, for example under stress,
remains to be determined.
The recovery of FHF cardiomyogenesis suggests that Mef2ca
and Mef2cb are redundant during FHF development, but indicates
a more prominent role for Mef2ca in FHF development. At 24 hpf,
we detect strong mef2cb mRNA at both the arterial and venous
poles, A similar pattern was observed in Atlantic cod, Gadus
morhua, that has two Mef2c paralogues, each expressed strongly
in a single cardiac pole at heart tube stage (Torgersen et al., 2011).
This is where SHF precursors reside (de Pater et al., 2009; Zhou et
al., 2011). The mef2cb expression pattern suggests a more promi-
nent role at the cardiac poles. Lazic and Scott (2011) described an
arterial pole defect using mef2cb MO; we found the same result
with our distinct mef2cb MO. However, the likely null mef2cbfh288
mutant has an apparently normal heart and grows well to a viable
and fertile adult. This shows that although distinct regulatory
elements cause distinct expression of each gene, a genetic
redundancy of Mef2ca and Mef2cb function exist for both early/
central FHF and later-added/polar SHF CMs.
How can one explain the cardiac pole-speciﬁc defects in
mef2cb morphants? Clearly, the MOs work to knockdown Mef2cb
protein, as Mef2c immunreactivity is ablated when they are used
in combination with the mef2camutant. Moreover, the absence of
Mef2c protein and the early stop codon in the mef2cb mutant
make it highly likely to be null. We hypothesise that the cardiac
pole defects arise from a non-speciﬁc effect of the MO added to a
loss of Mef2cb function that preferentially sensitizes CMs at the
cardiac poles.
Given time, the residual CMs in doublemef2ca;mef2cbmutants
can reach their normal position, aggregate, take on ventricular or
atrial character, form small tubular structures, beat and even
recruit non-myocardial cells into bulbus arteriosus. As discussed
above, Mef2aa may contribute towards this residual differentia-
tion. Mef2aa is expressed later than the two Mef2cs in zebraﬁsh
heart, and we detected mef2aa mRNA only in differentiated CMs.
Consistent with this, Mef2aa knockdown causes late cardiac
defects relating to contractility (Wang et al., 2005). So late
recovery of CMs in double mutants may reﬂect independent
activation of mef2aa. Alternatively, other factors such as GATAs
and Hand2 may be sufﬁcient to slowly rescue a few cells to CM
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only at the heart tube stage, whereas Mef2c (and Mef2b) are
expressed in pre-cardiac mesoderm, (Edmondson et al., 1994).
We speculate that redundancy between Mef2c and Mef2b may
explain the ability of CMs in early heart development of Mef2c
knockout mice. Mef2a null mice exhibit perinatal lethality from an
array of cardiovascular defects (Ewen et al., 2011; Naya et al., 2002).
Thus, expression and function of zebraﬁsh Mef2c and Mef2a ortho-
logues appear conserved between ﬁsh and mammals.
Mef2cb can drive ectopic skeletal myogenesis
Our data show that over-expression of Mef2cb leads to ectopic
expression of both cardiac and skeletal muscle genes. Extra Mef2cb
in its normal location, induced by BAC injection, leads to ectopic
CMs within the heart ﬁeld, but not elsewhere. Strikingly, however,
the entire cardiogenic region appears able to up-regulate bmp4
expression in response to Mef2cb, when it is introduced early by
mef2cb mRNA injection, but does not undergo extensive ectopic
cardiomyogenesis. This ﬁnding suggests that the ability of Mef2 to
drive CM differentiation is under tight additional controls.
Elsewhere in the embryo, particularly, but not exclusively, in
head mesoderm,mef2cbmRNA over-expression causes high levels
of conversion of cells to skeletal muscle. This effect is efﬁcient,
comparable to that of myod or mrf4 mRNA injection (Hinits et al.,
2009; Osborn et al., 2011), and can lead to loss of myocardial
markers, possibly through conversion of early cranial mesoderm
to skeletal muscle before it attains the character of the cardio-
genic region. The distinct action of Mef2cb over-expression in the
cardiogenic and other regions of the embryo suggests that the
activity of Mef2cb within a cell is strongly inﬂuenced by other
signals/molecules involved in head mesoderm patterning
((Tzahor and Evans, 2011) and others).
Our ﬁndings indicate a potential role for Mef2 as a skeletal
muscle determination factor, and is reminscent of the observation
that MEF2A can initiate skeletal myogenesis in some circum-
stances (Kaushal et al., 1994). However, other studies have shown
that Mef2c alone is unable to activate the myogenic program, but
requires Myod or another MRF (Black et al., 1998; Molkentin
et al., 1995). As no MRFs are expressed in the zebraﬁsh head
region prior to 24 hpf, it appears that Mef2cb can trigger the MRF
expression required for efﬁcient enhancement of terminal muscle
differentiation by Mef2s (della Gaspera et al., 2009; Molkentin et al.,
1995). Indeed, Xenopus Mef2a can activate the Myod promoter
(Wong et al., 1994). In Drosophila, Dmef2 is a key regulator of body
wall striated myogenesis and does not require on MRF (Gunthorpe
et al., 1999; Lin et al., 1997a). In C. elegans, by contrast, Mef2 is
dispensible for myogenesis (Dichoso et al., 2000). It remains to be
established whether the ability of Mef2cb is shared by other Mef2
factors and/or plays a role during development of any vertebrate
skeletal muscle in the wild type situation.
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